rs38855

Variant summary

Our verdict is Benign. The variant received -12 ACMG points: 0P and 12B. BP4_StrongBA1

The NM_000245.4(MET):​c.1201-13678A>G variant causes a intron change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.407 in 152,092 control chromosomes in the GnomAD database, including 13,920 homozygotes. In-silico tool predicts a benign outcome for this variant. No clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar.

Frequency

Genomes: 𝑓 0.41 ( 13920 hom., cov: 32)

Consequence

MET
NM_000245.4 intron

Scores

2

Clinical Significance

Not reported in ClinVar

Conservation

PhyloP100: -0.344

Publications

59 publications found
Variant links:
Genes affected
MET (HGNC:7029): (MET proto-oncogene, receptor tyrosine kinase) This gene encodes a member of the receptor tyrosine kinase family of proteins and the product of the proto-oncogene MET. The encoded preproprotein is proteolytically processed to generate alpha and beta subunits that are linked via disulfide bonds to form the mature receptor. Further processing of the beta subunit results in the formation of the M10 peptide, which has been shown to reduce lung fibrosis. Binding of its ligand, hepatocyte growth factor, induces dimerization and activation of the receptor, which plays a role in cellular survival, embryogenesis, and cellular migration and invasion. Mutations in this gene are associated with papillary renal cell carcinoma, hepatocellular carcinoma, and various head and neck cancers. Amplification and overexpression of this gene are also associated with multiple human cancers. [provided by RefSeq, May 2016]
COMETT (HGNC:51196): (cytosolic oncogenic antisense to MET transcript) This gene encodes a natural antisense transcript highly expressed in papillary thyroid carcinomas harboring BRAF V600E mutation or RET gene rearrangements. This lncRNA induces the downstream MAPK pathway and is part of a co-expression network including different oncogenes belonging to the MAPK and PI3H/AKT pathways. In thyroid carcinomas, this gene has oncogenic properties associated with increased proliferation and drug resistance. [provided by RefSeq, Jan 2020]

Genome browser will be placed here

ACMG classification

Classification was made for transcript

Our verdict: Benign. The variant received -12 ACMG points.

BP4
Computational evidence support a benign effect (BayesDel_noAF=-0.89).
BA1
GnomAd4 highest subpopulation (EAS) allele frequency at 95% confidence interval = 0.566 is higher than 0.05.

Transcripts

RefSeq

Gene Transcript HGVSc HGVSp Effect Exon rank MANE Protein UniProt
METNM_000245.4 linkc.1201-13678A>G intron_variant Intron 2 of 20 ENST00000397752.8 NP_000236.2

Ensembl

Gene Transcript HGVSc HGVSp Effect Exon rank TSL MANE Protein Appris UniProt
METENST00000397752.8 linkc.1201-13678A>G intron_variant Intron 2 of 20 1 NM_000245.4 ENSP00000380860.3

Frequencies

GnomAD3 genomes
AF:
0.408
AC:
61950
AN:
151974
Hom.:
13926
Cov.:
32
show subpopulations
Gnomad AFR
AF:
0.202
Gnomad AMI
AF:
0.298
Gnomad AMR
AF:
0.534
Gnomad ASJ
AF:
0.468
Gnomad EAS
AF:
0.583
Gnomad SAS
AF:
0.534
Gnomad FIN
AF:
0.448
Gnomad MID
AF:
0.434
Gnomad NFE
AF:
0.474
Gnomad OTH
AF:
0.431
We have no GnomAD4 exomes data on this position. Probably position not covered by the project.
GnomAD4 genome
AF:
0.407
AC:
61967
AN:
152092
Hom.:
13920
Cov.:
32
AF XY:
0.414
AC XY:
30796
AN XY:
74340
show subpopulations
African (AFR)
AF:
0.202
AC:
8380
AN:
41516
American (AMR)
AF:
0.534
AC:
8155
AN:
15260
Ashkenazi Jewish (ASJ)
AF:
0.468
AC:
1622
AN:
3466
East Asian (EAS)
AF:
0.584
AC:
3027
AN:
5186
South Asian (SAS)
AF:
0.533
AC:
2561
AN:
4808
European-Finnish (FIN)
AF:
0.448
AC:
4729
AN:
10552
Middle Eastern (MID)
AF:
0.418
AC:
123
AN:
294
European-Non Finnish (NFE)
AF:
0.473
AC:
32189
AN:
67984
Other (OTH)
AF:
0.430
AC:
909
AN:
2114
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.503
Heterozygous variant carriers
0
1775
3550
5326
7101
8876
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Genome Het
Genome Hom
Variant carriers
0
596
1192
1788
2384
2980
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
Alfa
AF:
0.455
Hom.:
71200
Bravo
AF:
0.403

ClinVar

Not reported in ClinVar

Computational scores

Source: dbNSFP v4.3

Name
Calibrated prediction
Score
Prediction
BayesDel_noAF
Benign
-0.89
CADD
Benign
0.51
DANN
Benign
0.61
PhyloP100
-0.34
Mutation Taster
=100/0
polymorphism (auto)

Splicing

Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
0.0
Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

Other links and lift over

dbSNP: rs38855; hg19: chr7-116358044; API